20 March 2017 in Journal of Clinical Investigation
Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 are among the first genetic alterations observed during the development of lower-grade glioma (LGG). LGG-associated IDH mutations confer gain-of-function activity by converting α-ketoglutarate to the oncometabolite R-2-hydroxyglutarate (2HG). Clinical samples and gene expression data from The Cancer Genome Atlas (TCGA) demonstrate reduced expression of cytotoxic T lymphocyte–associated genes and IFN-γ–inducible chemokines, including CXCL10, in IDH-mutated (IDH-MUT) tumors compared with IDH-WT tumors. Given these findings, we have investigated the impact of IDH mutations on the immunological milieu in LGG. In immortalized normal human astrocytes (NHAs) and syngeneic mouse glioma models, the introduction of mutant IDH1 or treatment with 2HG reduced levels of CXCL10, which was associated with decreased production of STAT1, a regulator of CXCL10. Expression of mutant IDH1 also suppressed the accumulation of T cells in tumor sites. Reductions in CXCL10 and T cell accumulation were reversed by IDH-C35, a specific inhibitor of mutant IDH1. Furthermore, IDH-C35 enhanced the efficacy of vaccine immunotherapy in mice bearing IDH-MUT gliomas. Our findings demonstrate a mechanism of immune evasion in IDH-MUT gliomas and suggest that specific inhibitors of mutant IDH may improve the efficacy of immunotherapy in patients with IDH-MUT gliomas.
4 December 2019 in Science Translational Medicine
Age-related breakdown of blood-brain barrier activates astrocytic TGFβ signaling to cause neural dysfunction and cognitive impairment.
4 December 2017 in Journal of Experimental Medicine
The median overall survival for children with diffuse intrinsic pontine glioma (DIPG) is less than one year. The majority of diffuse midline gliomas, including more than 70% of DIPGs, harbor an amino acid substitution from lysine (K) to methionine (M) at position 27 of histone 3 variant 3 (H3.3). From a CD8+ T cell clone established by stimulation of HLA-A2+ CD8+ T cells with synthetic peptide encompassing the H3.3K27M mutation, complementary DNA for T cell receptor (TCR) α- and β-chains were cloned into a retroviral vector. TCR-transduced HLA-A2+ T cells efficiently killed HLA-A2+H3.3K27M+ glioma cells in an antigen- and HLA-specific manner. Adoptive transfer of TCR-transduced T cells significantly suppressed the progression of glioma xenografts in mice. Alanine-scanning assays suggested the absence of known human proteins sharing the key amino acid residues required for recognition by the TCR, suggesting that the TCR could be safely used in patients. These data provide us with a strong basis for developing T cell–based therapy targeting this shared neoepitope.
1 February 2019 in bioRxiv
Aging involves a decline in neural function that contributes to cognitive impairment and disease. However, the mechanisms underlying the transition from a young-and-healthy to aged-and-dysfunctional brain are not well understood. Here, we report breakdown of the vascular blood-brain barrier (BBB) in aging humans and rodents, which begins as early as middle age and progresses to the end of the lifespan. Gain-of-function and loss-of-function manipulations show that this BBB dysfunction triggers hyperactivation of transforming growth factor β (TGFβ) signaling in astrocytes, which is necessary and sufficient to cause neural dysfunction and age-related pathology. Specifically, infusion of the serum protein albumin into the young brain (mimicking BBB leakiness) induced astrocytic TGFβ signaling and an aged brain phenotype including aberrant electrocorticographic activity, vulnerability to seizures, and cognitive impairment. Furthermore, conditional genetic knockdown of astrocytic TGFβ receptors, or pharmacological inhibition of TGFβ signaling, reversed these symptomatic outcomes in aged mice. Finally, we found that this same signaling pathway is activated in aging human subjects with BBB dysfunction. Our study identifies dysfunction in the neurovascular unit as one of the earliest triggers of neurological aging, and demonstrates that the aging brain may retain considerable latent capacity which can be revitalized by therapeutic inhibition of TGFβ signaling.
6 November 2017 in Neuro-Oncology
Myeloid Derived Suppressor Cells (MDSCs) are present in most solid tumors, including glioblastoma (GBM), where they can block the activation of tumor-reactive T-cells and support tumor growth. Our lab and others have demonstrated the important roles of cyclooxygenase (COX)-2 as well as its enzymatic product, prostaglandin E2 (PGE2), in MDSC development, accumulation, and function. PGE2 mediates cellular responses through its receptors, EP1-EP4, of which EP4 is known to play an important role in anti-tumor immune responses. We therefore evaluated the impact of ONO-AE3-208, an EP4 antagonist, on MDSC function, tumor growth, and T-cell activation in gliomas. Our in vitro studies demonstrated that while PGE2 and ONO-AE3-208 treatment did not alter the growth of SB28 mouse glioma cells, ONO-AE3-208 reversed the MDSC phenotype of bone marrow cells induced by PGE2 or SB28 glioma cell line-derived conditioned media. Similarly, ONO-AE3-208 restored interferon-γ production by CD8 T-cells following PGE2 treatment. In vivo, ONO-AE3-208 treatment significantly prolonged survival of mice bearing established intracranial C57BL/6-syngeneic SB28 gliomas in wild-type but not RAG1-/- immunodeficient mice. Immunostaining and flow cytometry revealed that ONO-AE3-208-treated gliomas were infiltrated by fewer MDSCs compared with control mice. RT-PCR analysis of glioma-infiltrating MDSCs demonstrated that ONO-AE3-208 treatment suppressed Arg1 and Cox2 expression levels in both Ly6G+ and Ly6C+ MDSC populations as well as Tgfb1 and Il4ra levels in Ly6G+ MDSCs. Consistently, glioma-infiltrating lymphocytes in ONO-AE3-208 treated tumor-bearing mice revealed enhanced Ifng expression compared with control mice, suggestive of enhanced T-cell activity. Finally, combination therapy using anti-PD1 monoclonal antibody with ONO-AE3-208 in the anti-PD1-sensitive GL261 glioma model resulted in further prolonged survival compared with anti-PD1 therapy alone. Our data demonstrate that ONO-AE3-208 may be useful in the treatment of glioma patients to suppress MDSCs and promote anti-tumor immunity.
1 November 2016 in Neuro-Oncology
We evaluated whether isocitrate dehydrogenase (IDH) mutations could directly alter the immune landscape of gliomas, possibly through production of the onco-metabolite, 2-hydroxygluterate (2HG). TCGA RNAseq data demonstrate reduced expression of CD8 T-cell, type-1 effector and chemokine genes in IDH-mutated (Mut) patients compared to IDH-wild-type (Wt) cases. Conversely, we observed no differences in B-cell, type-2 or regulatory T-cell-related genes between IDH-Wt and IDH-Mut cases. Normal human astrocyte (NHA) cells and syngeneic GL261 glioma models expressing the R132H mutated IDH1 (NHA-Mut and GL261-Mut, respectively) further demonstrated that the IDH1 mutation and 2HG directly reduce CXCL10 protein and migration of T-cells to the tumor site, which was reversed by an IDH-specific inhibitor, IDH-C35. Further, while mice receiving prophylactic peptide vaccination targeting glioma-associated antigens resulted in clearance of GL261-Wt tumors, vaccinated mice could not reject GL261-Mut tumors. Treatment of vaccinated mice bearing GL261-Mut tumors with IDH-C35 enhanced anti-tumor immunity and prolonged survival compared to mice receiving vaccine alone. Interestingly, both parental GL261 cells treated with 2HG and GL261-Mut cells demonstrated decreased amounts of STAT1 protein but not mRNA compared with untreated GL261-Wt cells, suggesting that STAT1, a known regulator of CXCL10, is regulated at the post-transcriptional level in IDH-Mut gliomas. Consistent with these findings, TCGA microRNA data demonstrated increased levels of miR-145, a known regulator of STAT1, in IDH-Mut compared with IDH-Wt cases. We next evaluated direct tumor extrinsic implications of the IDH1 mutation. 2HG, which is known to be present in the tumor microenvironment, directly induced a ~10 fold increase in miR-145-5p and reduced both STAT1 levels and CXCL10 secretion from primary and BV2 murine microglia. Our findings demonstrate both glioma-intrinsic and extrinsic mechanisms of immunosuppression in IDH-Mut gliomas and suggest that IDH inhibitors can be used to enhance T-cell migration to the tumor site in patients with IDH-Mut tumors.